id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-D-0307-0023,FDA,FDA-2012-D-0307,Reference 37-Regulation (EC) No 999_2001 of EU Parliament re Amendment to ‘‘Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;’’ Draft Guidance for Industry; Availability,Supporting & Related Material,Background Material,2017-12-22T05:00:00Z,2017,12,,,2020-02-25T15:38:29Z,,0,0,0900006482d5883c
FDA-2012-D-0307-0013,FDA,FDA-2012-D-0307,Reference 01 - Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and vCJD by blood and blood products re Amendment to ‘‘Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;’’ Draft Guidance for Industry; Availability,Supporting & Related Material,Background Material,2017-12-22T05:00:00Z,2017,12,,,2017-12-22T16:24:28Z,,0,0,0900006482d5882c
FDA-2012-D-0307-0010,FDA,FDA-2012-D-0307,Amendment to ‘‘Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;’’ Draft Guidance for Industry; Availability,Notice,Notice of Availability,2017-12-22T05:00:00Z,2017,12,2017-12-22T05:00:00Z,2018-03-23T03:59:59Z,2018-01-06T02:01:16Z,2017-27569,0,0,0900006482d56ac6
FDA-2012-D-0307-0016,FDA,FDA-2012-D-0307,Referecne 28-Gregori_et_al-2011-Transfusion re Amendment to ‘‘Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;’’ Draft Guidance for Industry; Availability,Supporting & Related Material,Background Material,2017-12-22T05:00:00Z,2017,12,,,2020-02-25T15:36:55Z,,0,0,0900006482d58830
FDA-2012-D-0307-0021,FDA,FDA-2012-D-0307,Reference 35-Schlicter S.J. (1997)TRAP Study re Amendment to ‘‘Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;’’ Draft Guidance for Industry; Availability,Supporting & Related Material,Background Material,2017-12-22T05:00:00Z,2017,12,,,2020-02-25T15:37:58Z,,0,0,0900006482d58838
FDA-2012-D-0307-0015,FDA,FDA-2012-D-0307,Reference 25-Yang_et_al-2017-Transfusion re Amendment to ‘‘Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;’’ Draft Guidance for Industry; Availability,Supporting & Related Material,Background Material,2017-12-22T05:00:00Z,2017,12,,,2020-02-25T15:36:39Z,,0,0,0900006482d5882e
FDA-2012-D-0307-0020,FDA,FDA-2012-D-0307,Reference 34-King_LR reduced RBC rxn_Tx_'04 re Amendment to ‘‘Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;’’ Draft Guidance for Industry; Availability,Supporting & Related Material,Background Material,2017-12-22T05:00:00Z,2017,12,,,2020-02-25T15:37:48Z,,0,0,0900006482d58835
FDA-2012-D-0307-0011,FDA,FDA-2012-D-0307,Amendment to ‘‘Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;’’ Draft Guidance for Industry; Availability,Other,Guidance,2017-12-22T05:00:00Z,2017,12,2017-12-22T05:00:00Z,2018-03-23T03:59:59Z,2024-11-07T01:15:24Z,,1,0,0900006482d58385
FDA-2012-D-0307-0019,FDA,FDA-2012-D-0307,Reference 32-Transfusion-medicine-epidemiology-review-tmer re Amendment to ‘‘Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;’’ Draft Guidance for Industry; Availability,Supporting & Related Material,Background Material,2017-12-22T05:00:00Z,2017,12,,,2020-02-25T15:37:39Z,,0,0,0900006482d58833
FDA-2012-D-0307-0018,FDA,FDA-2012-D-0307,Reference 31-McCutcheon_et_al-2011-PloSOne re Amendment to ‘‘Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;’’ Draft Guidance for Industry; Availability,Supporting & Related Material,Background Material,2017-12-22T05:00:00Z,2017,12,,,2020-02-25T15:37:23Z,,0,0,0900006482d58832
FDA-2012-D-0307-0022,FDA,FDA-2012-D-0307,Referenec 36-Bowden_LR v seroneg_Blood '95 re Amendment to ‘‘Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;’’ Draft Guidance for Industry; Availability,Supporting & Related Material,Background Material,2017-12-22T05:00:00Z,2017,12,,,2020-02-25T15:38:22Z,,0,0,0900006482d5883b
FDA-2012-D-0307-0024,FDA,FDA-2012-D-0307,Reference 38-FDA Transmissible Spongiform Encephalopathies Advisory Committee re Amendment to ‘‘Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;’’ Draft Guidance for Industry; Availability,Supporting & Related Material,Background Material,2017-12-22T05:00:00Z,2017,12,,,2020-02-25T15:38:38Z,,0,0,0900006482d5883d
FDA-2012-D-0307-0014,FDA,FDA-2012-D-0307,Reference 19-Swiss Med Wkly re Amendment to ‘‘Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;’’ Draft Guidance for Industry; Availability,Supporting & Related Material,Background Material,2017-12-22T05:00:00Z,2017,12,,,2017-12-22T16:24:59Z,,0,0,0900006482d5882d
FDA-2012-D-0307-0017,FDA,FDA-2012-D-0307,Reference 29-Harvey_et_al-2015-Transfusion re Amendment to ‘‘Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;’’ Draft Guidance for Industry; Availability,Supporting & Related Material,Background Material,2017-12-22T05:00:00Z,2017,12,,,2020-02-25T15:37:08Z,,0,0,0900006482d58831
FDA-2012-D-0307-0012,FDA,FDA-2012-D-0307,Reference List re Amendment to ‘‘Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;’’ Draft Guidance for Industry; Availability,Supporting & Related Material,Background Material,2017-12-22T05:00:00Z,2017,12,,,2017-12-22T16:24:07Z,,0,0,0900006482d587fd